头颈部鳞癌选择性颈部放疗剂量降低的随机临床试验:长期肿瘤结局更新
5年区域复发率40 Gy组为14.0%(95%CI 7.9;21.8),50 Gy组为7.5%(95%CI 3.3;14.0),p=0.10;5年总生存率两组分别为56.5%与49.6%(p=0.56)。两组在PTVelect内均仅观察到2例区域复发,降低PTVelect剂量看来安全,但研究检验效能不足。
要点
- 5年区域复发率40 Gy组14.0% vs 50 Gy组7.5%,差异无统计学意义(p=0.10)。
- 两组PTVelect内均仅2例区域复发,降低选择性颈部剂量未增加该区域复发。
- 5年总生存率两组无显著差异(56.5% vs 49.6%,p=0.56)。
核心结论
- 5年随访时两组总生存、局部复发、区域复发及远处转移均无统计学显著差异。
- 研究检验效能不足,无法明确证实非劣效性;但两组PTVelect内均仅2例复发,降低PTVelect剂量看来安全,值得进一步研究。
研究设计与样本
- 标准组PTVelect照射至EQD2 50 Gy,实验组PTVelect照射至EQD2 40 Gy;原发肿瘤及受累淋巴结按标准治疗至EQD2 70 Gy(PTVhigh)。
- 主要终点为放射性吞咽困难,次要终点为肿瘤控制;本次报告次要终点的长期随访结果。
主要发现
- 5年区域复发率40 Gy组为14.0%(95%CI 7.9;21.8),50 Gy组为7.5%(95%CI 3.3;14.0),p=0.10。
- 40 Gy组多数区域复发(9/13)投影在PTVhigh内,2例区域复发位于治疗体积之外。
- PTVelect照射至40 Gy者仅2例区域复发,与50 Gy PTVelect中复发数相同。
- 5年总生存率40 Gy组为56.5%(95%CI 45.7;65.9),50 Gy组为49.6%(95%CI 39.0;59.2),p=0.56。
关键数值与推荐
- 标准组选择性淋巴结区PTVelect处方剂量为EQD2 50 Gy,实验组为EQD2 40 Gy。
- 原发肿瘤及受累淋巴结PTVhigh处方剂量为EQD2 70 Gy。
- 区域复发通过将复发位置投影至初始放疗计划CT进行定位判定。
临床怎么用
- 在头颈鳞癌根治性放疗中,将选择性颈部PTVelect剂量降至EQD2 40 Gy未显示区域控制或生存获益的显著下降。
- 研究检验效能不足,尚不能据此确立非劣效性,降低PTVelect剂量应继续在研究中探索。
局限性
- 研究检验效能不足,无法明确证实非劣效性。
- 原文未报告主要终点放射性吞咽困难的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: A multicenter prospective randomized controlled trial was performed to investigate whether dose reduction to the elective nodal volume (PTVelect) in head and neck carcinoma reduces radiation-induced dysphagia, primary endpoint, without compromising tumor control, secondary endpoint. Here, we report on the long-term follow-up of the secondary endpoint (NCT01812486). MATERIALS AND METHODS: Two hundred patients treated with primary (chemo)radiotherapy (RT) were randomized (1:1) between the standard arm, irradiation to PTVelect up to an equivalent dose (EQD2) of 50 Gy and the experimental arm, irradiation to PTVelect up to EQD2 of 40 Gy. The primary tumor and involved nodes were treated according to the standard of care, EQD2 70 Gy (PTVhigh). Regional recurrences (RR) were projected on the initial RT planning-CT to identify the recurrence localization. RESULTS: The 5-year (5Y) RR was 14.0% (CI95% 7.9; 21.8) in the 40 Gy arm versus 7.5% (CI95% 3.3; 14.0) in the 50 Gy arm (p = 0.10). Majority of RR in the 40 Gy arm (9/13) were projected in PTVhigh and 2 RR were seen outside the treated RT volume. Only 2 RR occurred in PTVelect irradiated up to 40 Gy which was the same number as RR occurring in the 50 Gy PTVelect. The 5Y-overall survival (OS) was 56.5% (CI95% 45.7; 65.9) in the 40 Gy arm versus 49.6% (CI95% 39.0; 59.2) in the 50 Gy arm (p = 0.56). CONCLUSION: At 5-years, no statistically significant differences regarding OS, local recurrence, RR nor distant metastases were observed between both treatment arms. This study is underpowered to undoubtedly demonstrate non-inferiority. However, since in both arms only two RR in the PTVelect were observed, reducing the dose to PTVelect appears safe and should be further investigated.
引用
- Deschuymer S, Nevens D, Duprez F, et al. Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome. Radiother Oncol. 2020. PMID: 32044165. doi:10.1016/j.radonc.2020.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。